Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-463-5 | CAS number: 646-06-0
Endpoint summary
Administrative data
Description of key information
One subacute oral (gavage) toxicity study with rats is available. For the inhalation route, two subacute toxicity studies with rat and one subchronic study with rats is available. No repeated dose toxicity data for the dermal route are available.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 75 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEC
- 903 mg/m³
- Study duration:
- subchronic
- Species:
- rat
Additional information
In an oral gavage study, male and female rats were given 0, 75, 250, 750 or 2000 mg/kg bw of 1,3-Dioxolane during 14 days. For repeated dose oral toxicity, a NOAEL systemic of 75 mg/kg bw/day was observed in a subacute study with rats, based on observed reduced body weight gain in males and females, reduced leucocyte and lymphocyte counts in females and reduced platelet count in males observed at 250 mg/kg bw/day. No local effects were observed.
In a 13-week inhalation toxicity study, male and female rats were exposed to targeted concentrations of 0, 300, 1000 or 3000 ppm of 1,3-Dioxolane vapour. Satelite groups were allowed to recover for 8 weeks after the exposure period. For repeated dose inhalation toxicity, an overall NOAEC systemic of 298 ppm (0.90 mg/L or 903 mg/m³) was observed in the 90-day rat study, based on reduced WBC and lymphocyte count and increased platelet count in males and females, and reduced spleen weights in females at and above 1000 ppm (3.03 mg/L or 3030 mg/m³).
No local effects were observed.
Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: other
Repeated dose toxicity: inhalation - systemic effects (target organ) cardiovascular / hematological: other
Justification for classification or non-classification
Based on the oral NOAEL and NOAEC for systemic effects in the repeated dose toxicity studies, 1,3-dioxolane needs no classification for danger of serious health effects after prolonged exposure according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
